Le sumatriptan intranasal pour la migraine chez les enfants

Translated title of the contribution: Intranasal sumatriptan for migraine in children

Ran D. Goldman, Garth D. Meckler

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Question: I am seeing more and more children and adolescents with headaches that can be defined as migraine headache. I have read about intranasal sumatriptan as an abortive therapy. Is this an effective treatment? Answer: Acute migraine headache among children and adolescents is common and treatment is challenging. Intranasal sumatriptan is a safe and mostly effective option for children and adolescents. Currently the recommended dose is 20 mg for children who weigh more than 40 kg and 10 mg for children who weigh between 20 and 39 kg. Larger trials should be conducted to overcome the limitations of small sample sizes, potential low plasma concentration, and placebo effects witnessed in studies to date.

Translated title of the contributionIntranasal sumatriptan for migraine in children
Original languageFrench
Pages (from-to)435-437 and 439-441
JournalCanadian Family Physician
Volume61
Issue number5
StatePublished - May 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Family Practice

Fingerprint Dive into the research topics of 'Intranasal sumatriptan for migraine in children'. Together they form a unique fingerprint.

Cite this